Inventera Reports Phase 3 Success for World’s First MRA-Specific Contrast Agent, Challenging Gadolinium’s Dominance

Inventera announced on Sept. 21 that its MRA-specific contrast agent INV-002 (NEMO-103) met its primary efficacy endpoint in a domestic phase 3 clinical trial. No contrast agent is currently officially approved worldwide specifically for MRA. In clinical practice, physicians have relied on off-label use of intravenous gadolinium-based contrast agents, diluted at their discretion and administered into the joint space. If commercialized, INV-002 could become the first formally approved product to replace this practice.

An Iron-Based Contrast Agent Opens the Door to a Gadolinium-Free Era

INV-002 is an iron-based nano-MRI contrast agent that does not use conventional gadolinium. In recent years, the global medical community has focused increasingly on concerns about heavy-metal retention from gadolinium-based contrast agents in the brain and other parts of the body, environmental contamination and uncertainty in rare-earth supply chains. INV-002 avoids these toxicity concerns at the source and can be administered directly without a separate dilution process, drawing attention in the global market for gadolinium-free contrast agents.

The trial enrolled patients with known or suspected shoulder joint disease who required MR arthrography. The study aimed to recruit 85 patients at eight institutions, including Seoul National University Bundang Hospital, and ran from Sept. 23, 2025, through April 21, 2026. Inventera said in a filing with the electronic disclosure system DART that it had received the final clinical study report (CSR) from the contract research organization for the phase 3 trial conducted with approval from the Ministry of Food and Drug Safety.

All Three Measures Showed Results With P Values Below 0.0001

The primary endpoint comprised three quality measures—joint distention, contrast and sharpness—assessed by an independent central reader. MR arthrography performed 30 to 60 minutes after administration of NEMO-103 showed statistically significant improvement in all measures compared with noncontrast MRI. Specifically, the change in joint distention was 1.6±0.67 points, while contrast and sharpness were 1.1±0.26 points and 1.1±0.50 points, respectively. The p value was below 0.0001 for all three measures.

Oh Byung-yong, a researcher at Hanyang Securities, wrote in a Sept. 16 report that “if INV-002 receives marketing approval, it could enjoy a monopoly position as the only officially approved musculoskeletal contrast agent in South Korea.” He added, “From the perspective of physicians, there is a clear incentive to prescribe it because they could receive additional national health insurance reimbursement for administering the contrast agent while also improving diagnostic accuracy.” On Sept. 21, when news of the results emerged, Inventera shares surged 17.14% from the previous trading day to close at 11,890 won, approaching the daily upper limit during intraday trading.

Global Expansion to Begin in Earnest After Fourth-Quarter NDA Filing

Based on the results, Inventera plans to submit a new drug application (NDA) to the Ministry of Food and Drug Safety in the fourth quarter of 2026. If approved, the product is expected to launch officially in 2027. The company plans to expand the indications from its initial target, the shoulder joint, to the elbow, wrist and hip. Shin Tae-hyun, CEO of Inventera, said, “Successfully completing a phase 3 trial of a proprietary drug candidate is a meaningful achievement that demonstrates the company’s research and development capabilities,” adding, “We expect revenue generation to begin in earnest next year.”

The company’s global expansion strategy is also taking shape. Inventera has already secured U.S. Food and Drug Administration approval of the investigational new drug (IND) application for a phase 2b trial of INV-002 and is expected to begin the U.S. trial in earnest, building on its success in South Korea. In South Korea, the company has secured manufacturing and distribution capabilities through a partnership with Dongkook Life Science, the market-share leader in contrast agents. It has also established an export base by signing exclusive distribution rights agreements covering Japan, China and Southeast Asia. According to Grand View Research, the global MRI contrast agent market is projected to grow at an annual average rate of 7.8% from approximately $2.6 billion in 2026 to $4.3 billion in 2033, making the timing of INV-002’s global market entry favorable because it coincides with the market’s growth cycle. Inventera is also accelerating development of follow-on pipelines, including the lymphatic disease contrast agent INV-001 and the pancreatobiliary-specific contrast agent INV-003, as it seeks to become a leading global nanomedicine company.